S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
New CBOE “special perk” helps traders target income every weekend (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
New CBOE “special perk” helps traders target income every weekend (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
New CBOE “special perk” helps traders target income every weekend (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
New CBOE “special perk” helps traders target income every weekend (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy

Cerevel Therapeutics Stock Price, News & Analysis (NASDAQ:CERE)

$26.00
+0.07 (+0.27%)
(As of 12/1/2023 ET)
Compare
Today's Range
$25.28
$26.15
50-Day Range
$20.27
$26.36
52-Week Range
$19.59
$35.98
Volume
1.60 million shs
Average Volume
675,409 shs
Market Capitalization
$4.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.33

Cerevel Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
24.4% Upside
$32.33 Price Target
Short Interest
Bearish
9.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.10mentions of Cerevel Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$145 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.52) to ($2.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

858th out of 953 stocks

Pharmaceutical Preparations Industry

416th out of 447 stocks


CERE stock logo

About Cerevel Therapeutics Stock (NASDAQ:CERE)

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CERE Stock Price History

CERE Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
This Mid-Cap Biotech Stock Could Rise More Than 40% From Here
See More Headlines
Receive CERE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Coal & Consumable Fuels
Sector
Medical
Current Symbol
NASDAQ:CERE
CUSIP
15677310
Fax
N/A
Employees
321
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.33
High Stock Price Target
$46.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+24.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-351,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.51 per share

Miscellaneous

Free Float
171,084,000
Market Cap
$4.69 billion
Optionable
Not Optionable
Beta
1.38
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. N. Anthony Coles Jr.Dr. N. Anthony Coles Jr. (Age 63)
    M.P.H., Executive Chairman
    Comp: $1.14M
  • Mr. Mark Bodenrader (Age 50)
    VP of Finance & Chief Accounting Officer
    Comp: $496.17k
  • Dr. John J. Renger Ph.D. (Age 54)
    Chief Scientific Officer
    Comp: $779.75k
  • Dr. Ramiro Sanchez M.D. (Age 62)
    Chief Medical Officer
    Comp: $805.13k
  • Mr. Ronald C. Renaud Jr.Mr. Ronald C. Renaud Jr. (Age 54)
    M.B.A., President, CEO & Director
  • Dr. Susan Altschuller M.B.A. (Age 41)
    Ph.D., Chief Financial Officer
  • Mr. Matthew Calistri
    Vice President of Investor Relations
  • Mr. Scott M. Akamine J.D. (Age 38)
    Chief Legal Officer & Corporate Secretary
    Comp: $444.74k
  • Mr. Kenneth A. DiPietro (Age 64)
    Chief Human Resources Officer
  • Ms. Kathleen Tregoning M.A. (Age 52)
    Chief Corporate Affairs Officer
    Comp: $600.79k














CERE Stock Analysis - Frequently Asked Questions

Should I buy or sell Cerevel Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CERE shares.
View CERE analyst ratings
or view top-rated stocks.

What is Cerevel Therapeutics' stock price target for 2024?

9 Wall Street research analysts have issued 12 month price objectives for Cerevel Therapeutics' shares. Their CERE share price targets range from $22.00 to $46.00. On average, they predict the company's share price to reach $32.33 in the next year. This suggests a possible upside of 24.4% from the stock's current price.
View analysts price targets for CERE
or view top-rated stocks among Wall Street analysts.

How have CERE shares performed in 2023?

Cerevel Therapeutics' stock was trading at $31.54 at the beginning of 2023. Since then, CERE stock has decreased by 17.6% and is now trading at $26.00.
View the best growth stocks for 2023 here
.

When is Cerevel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our CERE earnings forecast
.

How were Cerevel Therapeutics' earnings last quarter?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) issued its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.02. During the same period in the previous year, the company posted ($0.66) earnings per share.

What ETFs hold Cerevel Therapeutics' stock?

ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), iShares Neuroscience and Healthcare ETF (IBRN) and Principal Healthcare Innovators ETF (BTEC).Harbor Health Care ETF (MEDI).

What other stocks do shareholders of Cerevel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).

Who are Cerevel Therapeutics' major shareholders?

Cerevel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (13.10%), Rock Springs Capital Management LP (1.40%), Adage Capital Partners GP L.L.C. (0.84%), Westfield Capital Management Co. LP (0.54%), Affinity Asset Advisors LLC (0.38%) and Avidity Partners Management LP (0.36%). Insiders that own company stock include Abraham Ceesay, Bain Capital Investors Llc, Deval L Patrick, Gabrielle Sulzberger, John Renger, Marijn E Dekkers, Mark Bodenrader, N Anthony Coles, Paul D Burgess, Perceptive Advisors Llc and Ronald C Renaud Jr.
View institutional ownership trends
.

How do I buy shares of Cerevel Therapeutics?

Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CERE) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -